A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Publication | Open Access

DOI Full Paper Access

111

Citations

References

2021

Year

Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Reyes Bernabé,

Annals of Oncology

Advanced NsclcBooster TrialNovel TherapyMedicinePathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerT790m Mutations